Androgen deprivation therapy induces androgen receptor-dependent upregulation of Egr1 in prostate cancers

Bin Xu; Gusheng Tang; Chengwu Xiao; Linhui Wang; Qing Yang; Yinghao Sun
June 2014
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 6, p2883
Academic Journal
No abstract available.


Related Articles

  • ADT-chemo combo cuts time to progression in PCa. Nierengarten, Mary Beth // Urology Times;7/1/2005, Vol. 33 Issue 8, p1 

    Cites a study which found that administering androgen deprivation therapy concurrently with paclitaxel is more effective than sequential treatment in androgen-dependent prostate cancer. Statement of lead author Bernie Eigl regarding the outcome; Lack of castration response in the mice used in...

  • Erratum.  // JNCI: Journal of the National Cancer Institute;Jun2011, Vol. 103 Issue 11, p906 

    A correction to the article "Risk of Colorectal Cancer in Men on Long-term Androgen Deprivation Therapy for Prostate Cancer" in an issue is presented.

  • Fewer Prostate Cancer Patients Are Initiating ADT, Data Shows.  // Renal & Urology News;Feb2012, Vol. 11 Issue 2, p24 

    The article reports on the decline on the use of androgen deprivation therapy (ADT) for prostate cancer (PCa).

  • Androgen deprivation therapy associated with dementia?  // Reactions Weekly;12/2/2016, Vol. 1630 Issue 1, p4 

    An abstract of the article "Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer" by F. Khosrow-Khavar and others is presented.

  • Length of androgen-deprivation therapy.  // Critical Care Alert;Aug2009 Pharmacology, p1 

    The article presents a study on the effectiveness of a long-term androgen-deprivation therapy in treating men with prostate cancer.

  • Acute kidney injury risk with androgen deprivation therapy.  // Reactions Weekly;8/10/2013, Issue 1465, p4 

    An abstract of the article "Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer," by F. Lapi and colleagues is presented.

  • Failure to Report Financial Disclosure Information. Lu-Yao, Grace; Albertsen, Peter; Weichung Shih; Siu-Long Yao // JAMA: Journal of the American Medical Association;1/7/2009, Vol. 301 Issue 1, p35 

    A authors of "Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer" report financial disclosures.

  • Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer. Shastri, Bhavin R.; Yaturu, Subhashini // Prostate Cancer (20903111);2011, p1 

    Prostate cancer is one of the most common malignancies in men. Charles Huggins and Clarence V. Hodges reported the androgen dependence of prostate cancer in 1941. That led to the utilization of androgen deprivation therapy as an important therapeutic modality to treat prostate cancer. Androgen...

  • Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer. Wilson, Shandra S.; Crawford, E. David. // Current Pharmaceutical Design;Mar2006, Vol. 12 Issue 7, p799 

    Ever since Huggins and Hodges won a Nobel Prize in 1966 for their work describing the relationship between testosterone and prostate cancer, androgen deprivation has continued to be an important component in the treatment of prostate cancer. Refinements in the therapy have occurred in the past...

  • Degarelix: a guide to its use in advanced prostate cancer.  // Drugs & Therapy Perspectives;Mar2010, Vol. 26 Issue 3, p6 

    Degarelix, a gonadotropin-releasing hormone receptor antagonist, is indicated as an androgen-deprivation therapy in patients with advanced prostate cancer. It effectively induces and maintains suppression of serum testosterone to castrate levels and is generally well tolerated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics